Keytruda PhIII failure in gastric cancer blights Merck's quest for frontline dominance
A year and a half after scoring an approval to use Keytruda in third-line gastric cancer, Merck has run into a wall trying to apply …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
